Ignite Creation Date:
2024-05-06 @ 3:52 PM
Last Modification Date:
2024-10-26 @ 1:58 PM
Study NCT ID:
NCT04785742
Status:
UNKNOWN
Last Update Posted:
2021-03-08
First Post:
2021-01-25
Brief Title:
Almonertinib for Advanced NSCLC Patients With Rare Mutations in EGFR
Sponsor:
Sun Yat-sen University
Organization:
Sun Yat-sen University
Study Overview
Official Title:
An Open Multicenter Phase II Clinical Study to Evaluate the Safety and Efficacy of Almonertinib in Patients With Advanced NSCLC With Rare Mutations in EGFR
Status:
UNKNOWN
Status Verified Date:
2021-03
Last Known Status:
ENROLLING_BY_INVITATION
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a multicenter open phase II clinical trial evaluating the safety and efficacy of high-dose almonertinib in the treatment of rare mutations in locally advanced or metastatic NSCLC patients with EGFR mutations excluding exon 19 deletion or rare mutations outside L858R Patients showed EGFR mutations by tissue or blood tests excluding exon 19 deletion or rare mutations other than L858R of which 20 exon 20INS mutations and rare mutations other than 20Ins were classified as two covariates High-dose amitinib was used for treatment to evaluate the safety and efficacy of the treatment regimen
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None